Test Code APCRR Activated Protein C Resistance V, with Reflex to Factor V Leiden, Blood and Plasma
Useful For
Evaluating patients with incident or recurrent venous thromboembolism (VTE)
Evaluating individuals with a family history of VTE
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| APCRV | Activated Protein Resistance V, P | Yes | Yes |
| SC018 | Whole Blood | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| F5DNA | Factor V Leiden (R506Q) Mutation, B | Yes | No |
| F5DNI | APCRV/F5DNA Summary Interpretation | No | No |
Testing Algorithm
If the assay ratio is abnormal, then factor V Leiden variant analysis will be performed at an additional charge.
When the activated protein C resistance V is abnormal or indeterminate and the factor V Leiden variant assay is performed, a summary interpretation will be provided.
Special Instructions
Method Name
Optical Clot-Based
Reporting Name
APCRV, w/Reflex, PSpecimen Type
Plasma Na CitWhole blood
Ordering Guidance
Although the APC-resistance assay can be performed in the absence of other coagulation tests and clinical information, it is most reliably performed as part of a consultative coagulation test panel with interpretive reporting (including appropriate testing of the same specimen to evaluate for the presence or absence of coagulation abnormalities or conditions that may affect interpretation of the APC-resistance assay); see AATHR / Thrombophilia Profile, Plasma and Whole Blood.
Necessary Information
Specimen Required
Blood and plasma are required.
Patient Preparation: Fasting: 8 hours, preferred but not required
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD) or light-blue top (3.2% sodium citrate)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Polypropylene plastic vial
Specimen Volume: 1 mL Platelet-poor plasma
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Within 4 hours of collection, centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into separate plastic vial leaving 0.25 mL in the bottom of centrifuged vial.
4. Immediately freeze plasma at -20° C, or ideally, at -40° C or below.
Additional Information:
1. A double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Minimum Volume
Platelet-poor plasma: 0.5 mL; Whole blood: 3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
| Whole blood | Ambient (preferred) | 14 days |
| Frozen | 14 days | |
| Refrigerated | 14 days |
Reference Values
ACTIVATED PROTEIN C RESISTANCE V RATIO
≥2.3
Pediatric reference ranges have neither been established nor are available in scientific literature. The adult reference range likely would be applicable to children older than 6 months.
Interpretation
An activated protein C (APC) resistance ratio below 2.3 suggests abnormal resistance to APC of hereditary origin.
If the screening APC resistance test is abnormal, DNA-based testing for the factor V Leiden variant (p.Arg534Gln, formerly R506Q) is performed to confirm or exclude hereditary APC-resistance.
Clinical Reference
1. Nichols WL, Heit JA. Activated protein C resistance and thrombosis. Mayo Clin Proc. 1996;71(9):897-898
2. Dahlback B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol. 1997;34(3):217-234
3. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130(8):643-650. doi:10.7326/0003-4819-130-8-199904200-00004
4. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V leiden mutation testing. Genet Med. 2001;3(2):139-148. doi:10.1097/00125817-200103000-00009
5. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002;126(11):1304-1318. doi:10.5858/2002-126-1304-CUOFVL
6. Yohe S, Olson J. Thrombophilia: Assays and interpretation. In: Kottke-Marchant K, Davis B, eds. Laboratory Hematology Practice. Blackwell Publishing; 2012:492-508
7. Favaloro EJ, Lippi G, eds. Hemostasis and Thrombosis: Methods and Protocols. Humana Press; 2017
Day(s) Performed
Monday through Friday
Report Available
4 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
85307
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| APCRR | APCRV, w/Reflex, P | 13590-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| APCR | APCRV Ratio | 13590-5 |
| SC018 | Whole Blood | No LOINC Needed |
| INT55 | Interpretation | 48591-2 |
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Coagulation Patient Information (T675)
3. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.